Gland Pharma's revenue up by 30%; profit grew by 38% in Q2

Hyderabad Gland Pharma Limited, a generic injectable focused pharmaceutical company, has recorded a y-o-y revenue growth of 30 per cent and profit after tax of Rs 3,021 million, with a y-o-y profit after tax growth of 38 per cent for the quarter ended September 30, 2021.

Commenting on the results, Srinivas Sadu, MD & CEO of Gland Pharma said "We delivered a strong performance this quarter Q2 FY22. We continue to focus on revenue diversification across geographies, which is helping us further improve our manufacturing efficiencies because of benefits from scale as well as de-risking the business. With declining Covid-19 hospitalisations, we observed a shift in product mix. Our wide therapeutic portfolio helped us to sustain growth despite changing market demand. Our rich R&D pipeline is helping us maintain strong momentum of new product launches. We are on track to make four complex injectable filings in this financial year."